Predicting survival for men with clinically localized prostate cancer: What do we need in contemporary practice?

Cancer

Volumn 112, Issue 1, 2008, Pages 1-3

  Albertsen, Peter ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER REGISTRY; CANCER SURVIVAL; CLINICAL PRACTICE; EDITORIAL; GLEASON SCORE; HUMAN; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; TRANSURETHRAL RESECTION;

AGED; BIOPSY; ENGLAND; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 37449011035     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23107     Document Type: Editorial

References (8)

1. Kattan MW, Cuzick J, Fisher G, et al. A nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2007;110:69-74.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate specific antigen level of <4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878.
5. Albertsen PC, Hanley JA, Fine J. Twenty year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
6. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002;97:237-244.
7. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. Prostate, lung, colorectal and ovarian screening trial of the National Cancer Institute: history, organization and status. Control Clin Trials. 2000;21(6 suppl):251S-272S.
8. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167:1664-1669.